MIST 1.48 Milestone Pharmaceuticals Inc.
| Range: | 1.12-3.52 | Vol Avg: | 109231 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 1.73 | Cap: | 0.08B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu May 09 2019 | Empoloyees: | 47 | ||
| CUSIP: | 59935V107 | CIK: | 0001408443 | ISIN: | CA59935V1076 | Country: | CA |
| CEO: | Mr. Joseph G. Oliveto M.B.A. | Website: | https://www.milestonepharma.com | ||||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow